Hyperuricemia in pediatric malignancies before treatment

Area of Science:

• Pediatric Oncology
• Nephrology
• Clinical Chemistry

Background:

• Hyperuricemia is a common complication in pediatric malignancies.
• Early identification of hyperuricemia is crucial for managing potential complications like tumor lysis syndrome (TLS).

Purpose of the Study:

• To determine the prevalence and characteristics of hyperuricemia in children with newly diagnosed malignancies before treatment.
• To identify risk factors associated with hyperuricemia in this population.

Main Methods:

• Retrospective analysis of 119 pediatric patients with newly diagnosed malignancies.
• Hyperuricemia defined as uric acid (UA) levels > 2 standard deviations above age-specific mean values.
• Comparison of clinical and laboratory parameters between hyperuricemia-negative and -positive groups.

Main Results:

• 30.3% of patients exhibited hyperuricemia.
• Hyperuricemia was more frequent in males (36.8%) than females (21.6%).
• Highest prevalence observed in lymphoma and acute lymphoblastic leukemia (ALL) patients.
• Significantly higher blood urea nitrogen, creatinine, lactate dehydrogenase, and white blood cell counts (in leukemia) in hyperuricemia-positive patients.

Conclusions:

• Hyperuricemia is a significant finding in newly diagnosed pediatric malignancies.
• Identifying hyperuricemia pre-treatment aids in predicting patients at risk for tumor lysis syndrome (TLS).
• This data supports proactive monitoring and management strategies for pediatric cancer patients.